| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| ln Vitro |
The proliferation of HL-60 cells is dose-dependently inhibited by glaucocalyxin A (GlnA) and (GlnB), with IC50 values of roughly 6.15 and 5.86 µM, respectively, after 24 hours. Reactive oxygen species (ROS) buildup, DNA damage, G2/M phase cycle arrest, and HL-60 cell death can all be brought on by Gln A and B [1]. Through the induction of autophagy and death, GlnB suppresses the growth of human cervical cancer cells in vitro. This process may be facilitated by the Akt/phosphatidylinositol 4,5-bisphosphate 3-kinase pathway. The growth of cervical cancer cell lines HeLa and SiHa was dose-dependently reduced by GlnB therapy. Poly(ADP-ribose) polymerase 1 cleavage is enhanced and apoptotic cell populations are increased by GlnB. Additionally, GlnB promoted the cleavage of the light chain 3 II/I protein, indicating the induction of autophagy. Phosphatase and tensin homologs are expressed more when GlnB is administered, whereas phosphorylated protein kinase B is expressed less [2]. One of the five enantio-kaurinic acid diterpenoids, glaucocalyxin B (GLB), has the ability to significantly lower different levels of nitric oxide (NO), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, cyclic Oxygenase (COX)-2, and inducible nitric oxide, which is produced in microglia by lipopolysaccharide-activated oxidase synthase (iNOS) [3].
|
|---|---|
| References |
|
| Additional Infomation |
Glaucocalyxin B has been reported in Isodon japonicus and Isodon pharicus with data available.
|
| Molecular Formula |
C22H30O5
|
|---|---|
| Molecular Weight |
374.4706
|
| Exact Mass |
374.209
|
| CAS # |
80508-81-2
|
| PubChem CID |
14193399
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
509.1±50.0 °C at 760 mmHg
|
| Melting Point |
190.5-191 ºC
|
| Flash Point |
172.9±23.6 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.554
|
| LogP |
1.37
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
27
|
| Complexity |
752
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(=O)O[C@@H]1[C@H]2CC[C@@H]3[C@]1([C@@H](C[C@H]4[C@]3(CCC(=O)C4(C)C)C)O)C(=O)C2=C
|
| InChi Key |
LSUXOKVMORWDLT-KEXKRWMXSA-N
|
| InChi Code |
InChI=1S/C22H30O5/c1-11-13-6-7-14-21(5)9-8-16(24)20(3,4)15(21)10-17(25)22(14,18(11)26)19(13)27-12(2)23/h13-15,17,19,25H,1,6-10H2,2-5H3/t13-,14-,15+,17+,19+,21-,22-/m0/s1
|
| Chemical Name |
[(1R,2R,4S,9R,10S,13S,16R)-2-hydroxy-5,5,9-trimethyl-14-methylidene-6,15-dioxo-16-tetracyclo[11.2.1.01,10.04,9]hexadecanyl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~267.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6704 mL | 13.3522 mL | 26.7044 mL | |
| 5 mM | 0.5341 mL | 2.6704 mL | 5.3409 mL | |
| 10 mM | 0.2670 mL | 1.3352 mL | 2.6704 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
